An index of global companies expected to economically benefit from GLP-1 drug development, approval, or market adoption. This includes companies who are manufacturers in the GLP-1 pharmaceuticals business or are GLP-1 enablers. The index allocates 70% of its weight to a Principal Manufacturers segment and 30% to an Enablers segment.
Quick Links
As May 17, 2024 | Index Level | 3-Month | 6-Month | 1-Year | YTD |
Price Return | 1,516.6 | 6.8% | 24.9% | 29.7% | 19.4% |
Total Return | 1,594.5 | 7.6% | 26.0% | 31.8% | 20.4% |
Net Total Return | 1,576.1 | 7.4% | 25.7% | 31.3% | 20.2% |
Index Level | 1,516.6 |
---|---|
3-Month | 6.8% |
6-Month | 24.9% |
1-Year | 29.7% |
YTD | 19.4% |
Index Level | 1,594.5 |
---|---|
3-Month | 7.6% |
6-Month | 26.0% |
1-Year | 31.8% |
YTD | 20.4% |
Index Level | 1,576.1 |
---|---|
3-Month | 7.4% |
6-Month | 25.7% |
1-Year | 31.3% |
YTD | 20.2% |
As of May 17, 2024
Index Symbol (Price Return) | THINR |
Index Symbol (Total Return) | THINRT |
Index Symbol (Net Total Return) | THINRN |
Number of Constituents | 21 |
Market Capitalization | $2.62 Trillion |
Adjusted Market Capitalization | $2.42 Trillion |
Rebalancings | Quarterly |
Dividend Yield | 1.57% |
VettaFi's indexes are widely used by financial firms, industry stakeholders and professionals to support a variety of business functions. We offers a range of end-of-day and historical index data subscriptions.
Contact Us